Svenja Neumann

4.6k total citations · 2 hit papers
12 papers, 1.4k citations indexed

About

Svenja Neumann is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Pathology and Forensic Medicine. According to data from OpenAlex, Svenja Neumann has authored 12 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Public Health, Environmental and Occupational Health and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Svenja Neumann's work include CAR-T cell therapy research (10 papers), Acute Lymphoblastic Leukemia research (8 papers) and Lymphoma Diagnosis and Treatment (5 papers). Svenja Neumann is often cited by papers focused on CAR-T cell therapy research (10 papers), Acute Lymphoblastic Leukemia research (8 papers) and Lymphoma Diagnosis and Treatment (5 papers). Svenja Neumann collaborates with scholars based in Germany, United States and United Kingdom. Svenja Neumann's co-authors include Andreas Viardot, Ralf C. Bargou, Gerhard Zugmaier, Matthias Stelljes, Max S. Topp, Nicola Gökbuget, Monika Brüggemann, Dieter Hoelzer, Dirk Nagorsen and Albrecht Reichle and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Pancreas.

In The Last Decade

Svenja Neumann

12 papers receiving 1.3k citations

Hit Papers

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager... 2014 2026 2018 2022 2014 2016 100 200 300 400

Peers

Svenja Neumann
Nahla Farahat United Kingdom
Armin Ghobadi United States
Svenja Neumann
Citations per year, relative to Svenja Neumann Svenja Neumann (= 1×) peers Julia Stieglmaier

Countries citing papers authored by Svenja Neumann

Since Specialization
Citations

This map shows the geographic impact of Svenja Neumann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Svenja Neumann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Svenja Neumann more than expected).

Fields of papers citing papers by Svenja Neumann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Svenja Neumann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Svenja Neumann. The network helps show where Svenja Neumann may publish in the future.

Co-authorship network of co-authors of Svenja Neumann

This figure shows the co-authorship network connecting the top 25 collaborators of Svenja Neumann. A scholar is included among the top collaborators of Svenja Neumann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Svenja Neumann. Svenja Neumann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Viardot, Andreas, Marie-Elisabeth Goebeler, Georg Heß, et al.. (2016). Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 127(11). 1410–1416. 280 indexed citations breakdown →
2.
Zugmaier, Gerhard, Nicola Gökbuget, Matthias Klinger, et al.. (2015). Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood. 126(24). 2578–2584. 115 indexed citations
3.
Kantarjian, Hagop M., Nicola Gökbuget, Susan O’Brien, et al.. (2015). Factors influencing outcomes in patients (Pts) with relapsed/refractory b-precursor acute lymphoblastic leukemia (r/r ALL) treated with blinatumomab in a phase 2 study.. Journal of Clinical Oncology. 33(15_suppl). 7057–7057. 2 indexed citations
6.
Topp, Max S., Nicola Gökbuget, Gerhard Zugmaier, et al.. (2014). Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 32(36). 4134–4140. 488 indexed citations breakdown →
7.
Klinger, Matthias, Christian Brandl, Gerhard Zugmaier, et al.. (2012). Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 119(26). 6226–6233. 357 indexed citations
8.
Topp, Max S., Nicola Goekbuget, Gerhard Zugmaier, et al.. (2012). Effect of anti-CD19 BiTE blinatumomab on complete remission rate and overall survival in adult patients with relapsed/refractory B-precursor ALL.. Journal of Clinical Oncology. 30(15_suppl). 6500–6500. 15 indexed citations
10.
Topp, Max S., Nicola Goekbuget, Gerhard Zugmaier, et al.. (2011). Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate In Adult Patients with Relapsed B-Precursor ALL: Updated Results of An Ongoing Phase II Trial. Blood. 118(21). 252–252. 26 indexed citations
12.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026